176 related articles for article (PubMed ID: 25454820)
1. Deletion at 6q24.2-26 predicts longer survival of high-grade serous epithelial ovarian cancer patients.
Kamieniak MM; Rico D; Milne RL; Muñoz-Repeto I; Ibáñez K; Grillo MA; Domingo S; Borrego S; Cazorla A; García-Bueno JM; Hernando S; García-Donas J; Hernández-Agudo E; Y Cajal TR; Robles-Díaz L; Márquez-Rodas I; Cusidó M; Sáez R; Lacambra-Calvet C; Osorio A; Urioste M; Cigudosa JC; Paz-Ares L; Palacios J; Benítez J; García MJ
Mol Oncol; 2015 Feb; 9(2):422-36. PubMed ID: 25454820
[TBL] [Abstract][Full Text] [Related]
2. The NER-related gene GTF2H5 predicts survival in high-grade serous ovarian cancer patients.
Gayarre J; Kamieniak MM; Cazorla-Jiménez A; Muñoz-Repeto I; Borrego S; García-Donas J; Hernando S; Robles-Díaz L; García-Bueno JM; Ramón Y Cajal T; Hernández-Agudo E; Heredia Soto V; Márquez-Rodas I; Echarri MJ; Lacambra-Calvet C; Sáez R; Cusidó M; Redondo A; Paz-Ares L; Hardisson D; Mendiola M; Palacios J; Benítez J; García MJ
J Gynecol Oncol; 2016 Jan; 27(1):e7. PubMed ID: 26463438
[TBL] [Abstract][Full Text] [Related]
3. A Study of High-Grade Serous Ovarian Cancer Origins Implicates the SOX18 Transcription Factor in Tumor Development.
Lawrenson K; Fonseca MAS; Liu AY; Segato Dezem F; Lee JM; Lin X; Corona RI; Abbasi F; Vavra KC; Dinh HQ; Gill NK; Seo JH; Coetzee S; Lin YG; Pejovic T; Mhawech-Fauceglia P; Rowat AC; Drapkin R; Karlan BY; Hazelett DJ; Freedman ML; Gayther SA; Noushmehr H
Cell Rep; 2019 Dec; 29(11):3726-3735.e4. PubMed ID: 31825847
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of ICAM-1 Predicts Poor Survival in High-Grade Serous Ovarian Carcinoma: A Study Based on TCGA and GEO Databases and Tissue Microarray.
Wang S; Yin C; Zhang Y; Zhang L; Tao L; Liang W; Pang L; Fu R; Ding Y; Li F; Jia W
Biomed Res Int; 2019; 2019():2867372. PubMed ID: 31312656
[TBL] [Abstract][Full Text] [Related]
5. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer.
Strickland KC; Howitt BE; Shukla SA; Rodig S; Ritterhouse LL; Liu JF; Garber JE; Chowdhury D; Wu CJ; D'Andrea AD; Matulonis UA; Konstantinopoulos PA
Oncotarget; 2016 Mar; 7(12):13587-98. PubMed ID: 26871470
[TBL] [Abstract][Full Text] [Related]
6. A tumor DNA complex aberration index is an independent predictor of survival in breast and ovarian cancer.
Vollan HK; Rueda OM; Chin SF; Curtis C; Turashvili G; Shah S; Lingjærde OC; Yuan Y; Ng CK; Dunning MJ; Dicks E; Provenzano E; Sammut S; McKinney S; Ellis IO; Pinder S; Purushotham A; Murphy LC; Kristensen VN; ; Brenton JD; Pharoah PD; Børresen-Dale AL; Aparicio S; Caldas C
Mol Oncol; 2015 Jan; 9(1):115-27. PubMed ID: 25169931
[TBL] [Abstract][Full Text] [Related]
7. Exploring the clonal evolution of CD133/aldehyde-dehydrogenase-1 (ALDH1)-positive cancer stem-like cells from primary to recurrent high-grade serous ovarian cancer (HGSOC). A study of the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium.
Ruscito I; Cacsire Castillo-Tong D; Vergote I; Ignat I; Stanske M; Vanderstichele A; Ganapathi RN; Glajzer J; Kulbe H; Trillsch F; Mustea A; Kreuzinger C; Benedetti Panici P; Gourley C; Gabra H; Kessler M; Sehouli J; Darb-Esfahani S; Braicu EI
Eur J Cancer; 2017 Jul; 79():214-225. PubMed ID: 28525846
[TBL] [Abstract][Full Text] [Related]
8. CD56 (Neural Cell Adhesion Molecule) Expression in Ovarian Carcinomas: Association With High-Grade and Advanced Stage But Not With Neuroendocrine Differentiation.
Bösmüller HC; Wagner P; Pham DL; Fischer AK; Greif K; Beschorner C; Sipos B; Fend F; Staebler A
Int J Gynecol Cancer; 2017 Feb; 27(2):239-245. PubMed ID: 27984374
[TBL] [Abstract][Full Text] [Related]
9. A distinctive ovarian cancer molecular subgroup characterized by poor prognosis and somatic focal copy number amplifications at chromosome 19.
Sung CO; Song IH; Sohn I
Gynecol Oncol; 2014 Feb; 132(2):343-50. PubMed ID: 24321399
[TBL] [Abstract][Full Text] [Related]
10. Genomic Rearrangement Signatures and Clinical Outcomes in High-Grade Serous Ovarian Cancer.
Hillman RT; Chisholm GB; Lu KH; Futreal PA
J Natl Cancer Inst; 2018 Mar; 110(3):265-72. PubMed ID: 29584920
[TBL] [Abstract][Full Text] [Related]
11. Proteogenomic analysis of chemo-refractory high-grade serous ovarian cancer.
Chowdhury S; Kennedy JJ; Ivey RG; Murillo OD; Hosseini N; Song X; Petralia F; Calinawan A; Savage SR; Berry AB; Reva B; Ozbek U; Krek A; Ma W; da Veiga Leprevost F; Ji J; Yoo S; Lin C; Voytovich UJ; Huang Y; Lee SH; Bergan L; Lorentzen TD; Mesri M; Rodriguez H; Hoofnagle AN; Herbert ZT; Nesvizhskii AI; Zhang B; Whiteaker JR; Fenyo D; McKerrow W; Wang J; Schürer SC; Stathias V; Chen XS; Barcellos-Hoff MH; Starr TK; Winterhoff BJ; Nelson AC; Mok SC; Kaufmann SH; Drescher C; Cieslik M; Wang P; Birrer MJ; Paulovich AG
Cell; 2023 Aug; 186(16):3476-3498.e35. PubMed ID: 37541199
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of differential expression of angiogenic genes in women with high-grade serous ovarian carcinoma.
Siamakpour-Reihani S; Owzar K; Jiang C; Turner T; Deng Y; Bean SM; Horton JK; Berchuck A; Marks JR; Dewhirst MW; Alvarez Secord A
Gynecol Oncol; 2015 Oct; 139(1):23-9. PubMed ID: 26260910
[TBL] [Abstract][Full Text] [Related]
13. TP53 mutations, tetraploidy and homologous recombination repair defects in early stage high-grade serous ovarian cancer.
Chien J; Sicotte H; Fan JB; Humphray S; Cunningham JM; Kalli KR; Oberg AL; Hart SN; Li Y; Davila JI; Baheti S; Wang C; Dietmann S; Atkinson EJ; Asmann YW; Bell DA; Ota T; Tarabishy Y; Kuang R; Bibikova M; Cheetham RK; Grocock RJ; Swisher EM; Peden J; Bentley D; Kocher JP; Kaufmann SH; Hartmann LC; Shridhar V; Goode EL
Nucleic Acids Res; 2015 Aug; 43(14):6945-58. PubMed ID: 25916844
[TBL] [Abstract][Full Text] [Related]
14. HOXA4/HOXB3 gene expression signature as a biomarker of recurrence in patients with high-grade serous ovarian cancer following primary cytoreductive surgery and first-line adjuvant chemotherapy.
Miller KR; Patel JN; Zhang Q; Norris EJ; Symanowski J; Michener C; Sehouli J; Braicu I; Destephanis DD; Sutker AP; Jones W; Livasy CA; Biscotti C; Ganapathi RN; Tait DL; Ganapathi MK
Gynecol Oncol; 2018 Apr; 149(1):155-162. PubMed ID: 29402501
[TBL] [Abstract][Full Text] [Related]
15. Increased DHRS12 expression independently predicts poor survival in patients with high-grade serous ovarian cancer.
Zhang Y; Wu J; Jing H; Huang G; Dong J; Cui Z
Future Oncol; 2018 Oct; 14(25):2579-2588. PubMed ID: 29783891
[TBL] [Abstract][Full Text] [Related]
16. Integrin Subunit beta 8 (ITGB8) Upregulation Is an Independent Predictor of Unfavorable Survival of High-Grade Serous Ovarian Carcinoma Patients.
He J; Liu Y; Zhang L; Zhang H
Med Sci Monit; 2018 Dec; 24():8933-8940. PubMed ID: 30531684
[TBL] [Abstract][Full Text] [Related]
17. Pooled Clustering of High-Grade Serous Ovarian Cancer Gene Expression Leads to Novel Consensus Subtypes Associated with Survival and Surgical Outcomes.
Wang C; Armasu SM; Kalli KR; Maurer MJ; Heinzen EP; Keeney GL; Cliby WA; Oberg AL; Kaufmann SH; Goode EL
Clin Cancer Res; 2017 Aug; 23(15):4077-4085. PubMed ID: 28280090
[No Abstract] [Full Text] [Related]
18. Genetic alterations in epithelial ovarian tumors analyzed by comparative genomic hybridization.
Hauptmann S; Denkert C; Koch I; Petersen S; Schlüns K; Reles A; Dietel M; Petersen I
Hum Pathol; 2002 Jun; 33(6):632-41. PubMed ID: 12152163
[TBL] [Abstract][Full Text] [Related]
19. Chromosome 6 abnormalities in ovarian surface epithelial tumors of borderline malignancy suggest a genetic continuum in the progression model of ovarian neoplasms.
Tibiletti MG; Bernasconi B; Furlan D; Bressan P; Cerutti R; Facco C; Franchi M; Riva C; Cinquetti R; Capella C; Taramelli R
Clin Cancer Res; 2001 Nov; 7(11):3404-9. PubMed ID: 11705855
[TBL] [Abstract][Full Text] [Related]
20. Whole genome oligonucleotide-based array comparative genomic hybridization analysis identified fibroblast growth factor 1 as a prognostic marker for advanced-stage serous ovarian adenocarcinomas.
Birrer MJ; Johnson ME; Hao K; Wong KK; Park DC; Bell A; Welch WR; Berkowitz RS; Mok SC
J Clin Oncol; 2007 Jun; 25(16):2281-7. PubMed ID: 17538174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
